GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » IM Cannabis Corp (NAS:IMCC) » Definitions » Total Liabilities

IM Cannabis (IM Cannabis) Total Liabilities : $26.17 Mil (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is IM Cannabis Total Liabilities?

IM Cannabis's Total Liabilities for the quarter that ended in Dec. 2023 was $26.17 Mil.

IM Cannabis's quarterly Total Liabilities declined from Jun. 2023 ($25.75 Mil) to Sep. 2023 ($24.07 Mil) but then increased from Sep. 2023 ($24.07 Mil) to Dec. 2023 ($26.17 Mil).

IM Cannabis's annual Total Liabilities declined from Dec. 2021 ($64.41 Mil) to Dec. 2022 ($27.15 Mil) and declined from Dec. 2022 ($27.15 Mil) to Dec. 2023 ($26.17 Mil).


IM Cannabis Total Liabilities Historical Data

The historical data trend for IM Cannabis's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IM Cannabis Total Liabilities Chart

IM Cannabis Annual Data
Trend Apr13 Apr14 Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 19.91 64.41 27.15 26.17

IM Cannabis Quarterly Data
Jan19 Apr19 Jul19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.15 23.56 25.75 24.07 26.17

IM Cannabis Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

IM Cannabis's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=24.454+(0.901+0.028
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0.718+0.071)
=26.17

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=36.384-10.212
=26.17

IM Cannabis's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=24.454+(0.901+0.028
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0.718+0.071)
=26.17

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=36.384-10.212
=26.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IM Cannabis Total Liabilities Related Terms

Thank you for viewing the detailed overview of IM Cannabis's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


IM Cannabis (IM Cannabis) Business Description

Traded in Other Exchanges
Address
Central District, Kibbutz Glil Yam, ISR, 4690500
IM Cannabis Corp is a Canada-based international medical cannabis company. It offers government-licensed cannabis products, from generic to GMP-certified and pharmaceutical-grade, for both wholesale and retail clients. The majority of its revenues are generated from sales of medical cannabis products to customers in Israel and recreational cannabis in Canada. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.